Mitsubishi UFJ Trust & Banking
PTGX icon

Mitsubishi UFJ Trust & Banking’s Protagonist Therapeutics PTGX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,975
Closed -$330K – 1136
2025
Q2 		$330K Buy
+5,975
New +$287K ﹤0.01% 944

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's PTGX Position: Q3 2025 in Review

Mitsubishi UFJ Trust & Banking sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 5,975 shares — an estimated $330K sold.

Mitsubishi UFJ Trust & Banking first reported a position in PTGX in Q2 2025 and held it in 1 quarter. The position peaked at $330K in Q2 2025. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Mitsubishi UFJ Trust & Banking reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mitsubishi UFJ Trust & Banking sold 5,975 Protagonist Therapeutics shares in Q3 2025, an estimated $330K.
  • Mitsubishi UFJ Trust & Banking first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mitsubishi UFJ Trust & Banking's Protagonist Therapeutics position peaked at $330K in Q2 2025.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q3 2025, filed 31 Oct 2025.